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Abstract–The International Commission on Radiological Protection (ICRP) developed
effective dose as a quantity related to risk for occupational and public exposure. There was
a need for a similar dose quantity linked to risk for making everyday decisions relating to
medical procedures. Coefficients were developed to enable the calculation of doses to organs
and tissues, and effective doses for procedures in nuclear medicine and radiology during the
1980s and 1990s. Effective dose has provided a valuable tool that is now used in the estab-
lishment of guidelines for patient referral and justification of procedures, choice of appropri-
ate imaging techniques, and providing dose data on potential exposure of volunteers for
research studies, all of which require the benefits from the procedure to be weighed against
the risks. However, the approximations made in the derivation of effective dose are often
forgotten, and the uncertainties in calculations of risks are discussed. An ICRP report on
protection dose quantities has been prepared that provides more information on the applica-
tion of effective dose, and concludes that effective dose can be used as an approximate meas-
ure of possible risk. A discussion of the way in which it should be used is given here, with
applications for which it is considered suitable. Approaches to the evaluation of risk and
methods for conveying information on risk are also discussed.
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1. INTRODUCTION
The dose quantities for medical procedures using ionising radiations that are
measured cannot readily be used to compare exposures in relation to risk.
This paper does not necessarily reflect the views of the International Commission on Radiological
Protection.
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Radiation exposures are seldom uniform over the whole body and usually involve
irradiation of several organs and tissues; this has a significant effect on the relative
risks. However, the radiations used for diagnostic and interventional procedures are
always x rays, gamma rays, beta particles, or positrons. Therefore, the differences in
biological effectiveness of the radiations in damaging tissue are relatively small and
have less influence on the risk. The concept of combining doses to individual organs
weighted according to their sensitivity to induction of stochastic effects in order to
derive an effective dose linked to risk was first proposed in 1975 (Jacobi, 1975). The
International Commission on Radiological Protection (ICRP) developed this prin-
ciple further, and recommended derivation of a dose-equivalent limit based on the
total risk to all tissues irradiated, linked to stochastic effects derived from results of
epidemiological studies. The approach stems from the principle that the risk asso-
ciated with the dose quantity should be equal to that from a similar uniform dose to
the whole body. This was achieved by summing doses to individual tissues, each
modified by a tissue weighting factor based on an assessment of the risk from sto-
chastic effects, namely cancer and genetic effects (ICRP, 1977). A remainder was
included consisting of an average dose for other tissues that were potentially at risk
from cancer induction. The initial dose quantity was called the ‘effective dose equiva-
lent’ and was applied in the evaluation of doses received by radiation workers and
the public. The primary organs at risk that were included were the gonads for genetic
effects, and the breast, lung, and bone marrow for cancer, with lower weighting for
the thyroid and bone surfaces relating to malignancy. It was used to provide a
method for judging the acceptability of the level of risk in radiation work by allowing
comparisons of the risk from radiation exposure with the risks for other occupations,
as well as planning of operations and optimisation of procedures to keep dose levels
to radiation workers and the public at acceptable levels. The cancer risk data used in
derivation of the tissue weighting factors are largely from the Life Span Study of the
Japanese survivors from the atomic bombs detonated in 1945. The lifetime risks of
developing cancer from exposure of different organs compared with dose data, which
appear linear between doses of <100 mGy to several Gy, are extrapolated down to
low doses (ICRP, 2005; Shore et al., 2018). This linear no-threshold (LNT) model is
used to calculate the probability of radiation-induced cancer for organs and tissues
for which there are sufficient data (ICRP, 2007).
ICRP renamed the quantity ‘effective dose’ when the fundamental recommenda-
tions on radiological protection were updated (ICRP, 1991). Changes were made in
the organs/tissues included in the effective dose and the tissue weighting factors
because of growing evidence of links between cancers in other tissues and radiation
exposure identified through the Life Span Study. Further modifications in the for-
mulation were made in the last set of fundamental recommendations based on
changes in analyses of the epidemiological data and the calculation of radiation
detriment (ICRP, 2007). The weighting factors are rounded to facilitate calculation
in order to provide a radiation protection dose quantity that is easy to apply in
practice. Thus, effective dose is a protection quantity designed for easy application,
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rather than a scientific quantity that can be measured, and is acknowledged to be an
approximation with inherent uncertainties (Martin, 2007; McCollough et al., 2010).
2. DOSE QUANTITIES USED IN MEDICAL APPLICATIONS
2.1. Measurable dose quantities
Radiation is used in a wide range of applications in medical diagnosis and ther-
apy. For diagnostic and interventional x-ray applications, radiation doses received
by patients are recorded in terms of quantities that can be measured and are gener-
ally displayed on equipment consoles. For radiography and fluoroscopy, they take
the form of entrance surface air kerma, that relates to dose to the skin surface, and
kerma-area product (KAP; PKA), that gives a measure of all radiation incident on the
patient. For computed tomography (CT), they take the form of the CT dose index
that is associated with doses to the tissues within the section of the body being
imaged, and the dose length product (DLP) that gives a measure of dose from a
whole procedure. These measured quantities can be recorded and applied readily for
assessment of dose levels, and are used for collection of data in patient dose surveys,
comparisons of doses for examinations at different healthcare facilities, optimising
procedures, and setting diagnostic reference levels (Martin, 2011a; ICRP, 2017). In
fact, they are useful for most applications where a measure of dose is required, such
as for recording patient dose information in medical reports, as required by
European member states (EU, 2014) and for joint common accreditation in the
USA, and for tracking doses to individual patients accumulated over time (Rehani
et al., 2014). The activities of radionuclides, together with the type of radiopharma-
ceutical administered to each patient, fulfil the same roles in nuclear medicine.
2.2. The need for and evolution of effective dose in medicine
In medicine, imaging examinations using ionising radiations are performed on
different parts of the body to aid diagnosis and treatment of a wide range of diseases.
Judgements have to be made about examinations relating to the level of risk, but
radiation quantities that can be measured often give little indication of potential risk.
Comparison of KAP values for the chest and abdomen do not have much relevance,
nor do comparisons of KAP and DLP for the same body region, or the measured
dose for an x-ray procedure with the amount of radioactivity administered for a
nuclear medicine examination. In all these cases, the distributions of radiation doses
to organs and tissues within the body will be very different. There is a need for a dose
quantity that supplies some information on risk to inform decisions about the appro-
priateness of radiation exposures used for diagnosis and management of treatments
for large numbers of patients.
Effective dose was designed as a protection quantity to enable decisions to be
made about potential exposures of workers and the public, and to set dose limits,
constraints, and reference levels. However, ICRP acknowledged that it could provide
a useful measure of doses to nuclear medicine patients in whom radionuclides
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accumulated in various organs around the body, and that its use could facilitate
comparisons between different types of medical radiological investigation (ICRP,
1987). Since that time, ICRP Committees 2 and 3 have collaborated to derive coef-
ficients to enable absorbed doses to organs and tissues, and assessments of effective
doses received by nuclear medicine patients to be quantified in order to fill this gap.
The reports use biokinetic models developed from available data within a generic
framework to evaluate the activities of different radionuclides that are likely to accu-
mulate in different organs (e.g. ICRP, 1988, 2015). Radionuclide distributions and
transit times through different organs are evaluated and activity–time curves gener-
ated. These are used, together with mathematical models of the anatomy for a ref-
erence person, to obtain absorbed doses for all the organs and tissues within the
body from the accumulated activity in the ‘source’ organs. Coefficients have since
been published to enable calculation of organ and effective doses for diagnostic x-ray
procedures by a number of organisations, and these can be applied to the entrance
surface air kerma or KAP for radiography and fluoroscopy (Hart et al., 1994;
Ranniko et al., 1997; Kramer et al., 2004), or the DLP for CT (Ding et al., 2015;
Shrimpton et al., 2016). Values of effective dose calculated with these coefficients can
be used to compare doses from a wide range of medical procedures that expose
different regions of the body, and these have been instrumental in raising awareness
of dose levels from diagnostic imaging procedures among medical physicists, clin-
icians, and radiographers.
2.3. The application of effective dose to medical patients
Effective dose is now used in training medical professionals in radiological pro-
tection, and can provide a broad understanding of possible risks associated with
radiation exposures. It has provided a universal dose quantity that can be used as
a reference against which improvement in radiological protection in medical practice
can be judged, and gives an indication of radiation dose relating to possible risks to
health that can be understood by clinicians and non-specialists in radiological pro-
tection. The details of how, and for what purposes, effective dose is applied vary
across the world, but include decisions made as part of the process for justifying
imaging exposures for individual patients and optimising protection through selec-
tion of the most appropriate technique. Generic values of effective dose calculated
for common procedures provide a straightforward tool that can be used for making
these everyday decisions.
However, the application of effective dose to medical procedures is rather different
from occupational and public applications, in which the requirement is for a measure
relating to risk that can be used in the optimisation of protection below constraints
or reference levels. With medical x rays, the exposure is planned, limits on the region
of the body exposed are defined, and simulations are used to evaluate doses to
individual organs, although these are in reference anatomical phantoms rather
than the patient. Thus, more is known about the dose distributions from medical
exposures than those to workers. This creates the impression that the doses to
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patients are known with much greater certainty than they actually are, and has led to
users losing sight of the many approximations employed in the derivation of effective
dose (Martin, 2007; McCollough et al., 2010). In the use of effective dose for evalu-
ation of occupational and public doses, there had been little need to consider these
uncertainties.
3. UNCERTAINTIES IN CALCULATIONS OF EFFECTIVE
DOSE AND RISK
3.1. Approximations made in the derivation of effective dose and its
use in medicine
As effective dose can express dose in terms related to relative risk from exposures
of different parts of the body, it is admirably suited for application to medical expos-
ures. However, approximations involved in the derivation and uncertainties in the
calculation need to be taken into account in its application to assessment of doses to
patients.
3.1.1. Age and sex
The risk estimates to which effective dose relate have been derived for populations
of all ages, so while medical exposures may relate to individuals, effective dose
applies to a sex-averaged reference person exposed in the same way (ICRP, 2007).
3.1.2. Tissue weighting factors
As effective dose is a practical operational tool, the most important requirement is
for it to be simple to calculate and use. Tissue weighting factors are rounded approxi-
mations related to the risks that stem from epidemiological data that are judged to be
acceptable for deriving a radiation protection dose quantity. Differences from the
risks calculated from epidemiological data are an approximation that give another
source of inaccuracy.
3.1.3. Dose measurements
Values for effective dose are computed from the results of practical measurements
of dose quantities in which there are uncertainties. For example, for x-ray exposures,
there will be uncertainties not only in the tissue dose measurement itself, but also in
the extent of the region of the body exposed that relates to the size of the x-ray field.
3.1.4. Computations
The derivation of effective dose requires values for doses to all of the organs
exposed to be computed, and this is done via Monte Carlo simulations. There are
significant uncertainties in these calculations that combine with those in the bound-
aries of the radiation fields in radiology (Martin, 2007). For nuclear medicine exam-
inations, uncertainties in the radionuclide dose transit time curves include factors
such as the time that radioactivity remains in the bladder, which is dependent on the
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patient’s actions. They also depend on patient anatomy, which determines the prox-
imity of organs for which absorbed dose is being assessed to those in which radio-
activity accumulates (Martin, 2011b).
The net result is that there may be an uncertainty of 40% in values derived for
effective dose as a relative indicator of risk to a reference person when applied to
medical imaging procedures in general (Martin, 2007). For some diagnostic nuclear
medicine investigations where the dose to the target organ, or to the bladder and colon
irradiated during the excretion process, represents a significant proportion of the total
dose, the uncertainty may be50% (Martin, 2011b). When this is considered in terms
of radiation exposure and risk in general, the magnitude of the uncertainty is not
unreasonable, and effective dose provides a useful comparator for making overall
judgements about the relative risks from different types of medical procedure and
making comparisons with doses from other sources. However, because of the uncer-
tainties, effective dose should only be quoted to one significant figure for values less
than 1 mSv, and two significant figures for values above 1 mSv.
Effective dose is the only relatively simple way in which a dose with some link to
risk can be expressed, but users must acknowledge its approximate nature, use it as a
guide in making decisions and steering practice, and recognise that it has large
uncertainty and applies to a reference person rather than an individual.
Comparisons of effective doses for medical procedures with everyday exposures
from natural background radiation and from cosmic rays during a plane flight, to
which people can relate, is sometimes helpful. These comparisons can be particularly
useful in discussions with patients who have little or no knowledge about radiation,
and may have an unrealistic fear of the potential harm from an exposure.
When using effective dose, it should be borne in mind that the potential risk for
patients from medical exposures is generally lower than that for a reference popu-
lation due to their higher average age and the reduced life expectancy due to disease
(Loose et al., 2009). However, risks for paediatric patients are generally higher and
this potential increased sensitivity should be recognised (ICRP, 2013).
In medical examinations where only one organ is exposed, estimates of the dose to
that organ or tissue should be used instead of effective dose. Examples are radio-
logical imaging of anatomic areas outside the trunk, such as the breast in mammog-
raphy or the brain in head CT. This also applies to radioiodine uptake by the
thyroid, quoted in terms of absorbed dose to the thyroid, and gonad dose where
this makes up the majority of the dose received.
3.2. Use of effective dose in conveying radiation risk
Risks of cancer incidence relating to effective dose are quoted in the fundamental
recommendations of ICRP (ICRP, 2007). These are helpful in providing a calibra-
tion of effective dose in terms of risk. In a forthcoming ICRP publication on use of
the protection quantities, it is concluded that effective dose can be used as an
approximate measure of possible risk. This wording was chosen to emphasise the
uncertainties inherent in the estimation of risk, and to acknowledge that the doses
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under consideration are, in many cases, below the levels at which direct epidemio-
logical observations of excess cases of cancer are available.
3.2.1. LNT model
Effective dose employs the LNT model, as this is considered to be the best
approach to quantifying the risk–dose relationship on the basis of current knowledge
(ICRP, 2005; NCRP, 2018; Shore et al., 2018). By assuming that the lifetime risk of
cancer is directly proportional to the dose, doses from all radiation exposures can be
summed. This means that small radiation doses well below the level at which any
effect can be demonstrated are taken into account and considered to be potentially
harmful. It is not possible to prove a definitive form for the link between exposure
and cancer at these dose levels, as this would require study of populations of tens of
millions of individuals whose exposures were known, together with matched control
groups. The uncertainty in the LNT model applies to any calculation of risk at low
doses, whether calculated from effective dose or doses to individual organs.
3.2.2. Adjustments for exposed populations
Risks of cancer originate from epidemiological studies, predominantly of the
Japanese survivors of the atomic bombs detonated over Hiroshima and Nagasaki.
Recent cancer risk vs dose models have been constructed from mortality data for
leukaemia and cancer incidence data for solid tumours (BEIR, 2006; ICRP, 2007;
Berrington de González et al., 2012). Two approaches are used to obtain projections
of lifetime risk. The first, called the ‘excess absolute risk’ (EAR) or ‘additive risk
model’, assumes that the excess absolute risk is proportional to the dose to the tissue.
The second, called the ‘excess relative risk’ (ERR) or ‘multiplicative model’, includes
an adjustment linked to the relative rates of cancer incidence in the target population
and the unexposed study population (ICRP, 2007). The target population used by
ICRP aims to provide global average values, and bases its assessments on a com-
posite population comprising four Asian populations, two European populations,
and a US population. Risks for the breast are based on the EAR model, risks for the
thyroid and skin are based on the ERR model, risks for the lung are based on an
ERR:EAR weighting of 0.3:0.7, and risks for other organs are based on a 0.5:0.5
ratio. Decisions about the weighting stem from the expert opinion of members of the
committee formulating the values. Risks per unit organ dose published in BEIR
(2006) and Berrington de González et al. (2012) differ from those in ICRP (2007)
as they use a US population with slightly different factors (Martin, 2019).
3.2.3. Dose and dose rate effectiveness factor
Radiobiological experimental investigations have tended to show that risks are
reduced for fractionated or protracted exposures, suggesting that high-dose, acute
exposures may overestimate the risk of cancer induction. Therefore, in ICRP (2007),
the risk estimate is divided by 2.0, but this is again an approximation that stems from
earlier methods and views of Commission members. The value used in BEIR (2006)
and Berrington de González et al. (2012) for risk calculations is 1.5.
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3.2.4. Other uncertainties
There are other sources of uncertainty in any risk estimates. For example, there
will be interactions between radiation exposure and other cancer risk factors, notably
smoking history in the case of lung cancer, and reproductive history in the case of
female breast cancer. Another example is the assumption inherent in the application
of a single radiation weighting factor of 1 to describe the relative biological effect-
iveness for all photon radiations in the 30–200-keV range (Heyes et al., 2009) and
beta-particle radiations.
There has been a desire to quote risks from radiation exposure in numerical terms
in many countries, and effective dose has been used to calculate a figure for the excess
lifetime risk of cancer. However, even for the ICRP reference person, actual risks
might be three times higher or lower than the estimate, but the uncertainty could be
much greater given the lack of definitive proof for the LNT model at low doses. The
use of medical radiation has been increasing rapidly over the last 20 years, and there
is a need to try to reduce numbers of unnecessary exposures. In promotion of this
message, claims have been made quoting large numbers of additional cancers that
could result from this increase (Brenner and Hall, 2007; Berrington de González
et al., 2009). These numbers are derived using the BEIR (2006) model, but with
little account taken of the uncertainties in epidemiological data, the extrapolation
to low doses, or the reduced life expectancy of patients because of their illnesses.
Such numerical assessments can give a false impression of accuracy, and should be
appropriately caveated with consideration of uncertainties and background rates.
The use of general terms linked to possible levels of cancer risk, as shown in
Table 1, avoids the impression of precision in risk estimates. These terms are con-
sidered to be reasonable indications of the risk from cancer induction for those aged
between approximately 20 years and 60 years. When using these terms in discussions
about patients, the influence of their disease, condition, and age on life expectancy
should be taken into account.
3.3. Application of risks to individual patients
The risk estimates used in the derivation of effective dose have been age- and sex-
averaged. Some of the differences between risks for an individual and those for the
ICRP reference person can be taken into account if required. The differences are
listed below.
3.3.1. Age
Overall lifetime risks of cancer from radiation exposure decline with age, with
risks for exposure of children aged 0–10 years being approximately double those for
exposure in middle-aged adults (30–50 years), and those for the over 60 s being
approximately half. The greater radiosensitivity of tissues in children contribute to
their higher risk, but variations with age at exposure primarily reflect differences in
the remaining lifetime after exposure. There are substantial differences between
cancer types, with risks of lung cancer induction increasing in middle age, and
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risks of thyroid and female breast being high for the young and falling to a low level
by 30–40 years (ICRP, 2007).
3.3.2. Sex
Lifetime cancer risks differ for the two sexes, with the significant risks of breast
cancer applying virtually exclusively to females. In addition, risks of thyroid cancer
are four to five times greater in females, and risks of lung cancer are almost double.
For cancers such as colon and leukaemia, the risk in males is 40–50% higher.
3.3.3. Health status
Patients undergo examinations to investigate disease, and in many cases, the med-
ical risk from their condition is likely to reduce their life expectancy and therefore the
risk of radiation-induced cancer (Loose et al., 2009).
3.3.4. Genetic factors
There are known to be differences in genetic susceptibility to cancer, with certain
sections of the population likely to be more susceptible to cancer induction by
radiation.
Epidemiological data have been used to determine risks from exposure of individ-
ual organs and tissues within the body (BEIR, 2006; ICRP, 2007), so if amore accurate
Table 1. Dose ranges and terminology for describing the excess lifetime risks of cancer inci-
dence from different medical diagnostic procedures for adult patients of average age (30–39
years).
Effective
doses (mSv)
Risk of cancer
inferred from
LNT model*
Proposed term
for dose level
Examples of medical
radiation procedures
within different dose
categories
<0.1 <105 Negligible Radiographs of chest, femur,
shoulder limbs, neck, and teeth
0.1–1 105–104 Minimal or
extremely low
Radiographs of spine and trunk,
and 99mTc lung ventilation and
renal imaging
1–10 104–103 Very low CT scans of head and body, car-
diac angiography, and a variety of
nuclear medicine examinations
10–100 103–102 Low Multiple CT scans of trunk with
contrast and higher dose inter-
ventional procedures
100 s >102 based on
epidemiology
Moderate Multiple procedures and follow-
up studies
LNT, linear no-threshold; CT, computed tomography.
*Risk bands are lifetime detriment adjusted incidence to nearest order of magnitude.
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assessment of risk is deemed necessary, this can be calculated using the risk coefficients
for each organ and tissue separately, based on the age and sex of the exposed individ-
ual. Brenner (2008, 2012) proposed the use of the term ‘effective risk’ to describe an
approach to the summation of risks estimated in this way. However, while this
approach uses the available data on age- and sex-specificity of the different cancer
types, it does not take account of the large uncertainties described in Section 3.2.
4. APPLICATIONS OF EFFECTIVE DOSE IN MEDICINE
In its forthcoming publication on protection dose quantities, ICRP has set out the
purposes for which use of effective dose is recommended in medicine, and these are
given below.
4.1. Referral guidelines and justification of procedures
Effective dose provides information on relative magnitudes of doses from different
types of examination that can be used in referral guidelines and in justification of
techniques at national level. In addition, it can be used by clinicians in making
decisions as part of the justification of procedures for individual patients. Effective
dose provides sufficient information to allow clinicians to weigh the benefit from the
diagnostic information needed for management of the patient’s disease against the
potential risk from radiation exposure, taking account of the sex, age, medical risk
from their condition, and life expectancy (Loose et al., 2009).
4.2. Choice of imaging technique
Effective dose enables doses from procedures in which the dose distributions are
different to be compared (e.g. x ray and nuclear medicine). Decisions about which
technique to use will be based primarily on the type of information each will provide
for the potential benefit to the patient, but the relative effective dose is a secondary
factor that can be taken into account when appropriate.
4.3. Optimisation of technique
In general, effective dose is not the best quantity for making comparisons between
doses for similar techniques for which there are measurable quantities such as KAP
or DLP. However, if the dose distribution within the body changes, because of
radiographic projection, tube potential, or addition of a filter, effective dose may
be useful for evaluating changes in exposure of the different organs and tissues.
4.4. Doses to research volunteers
Before a research proposal is approved, the possible detriment for the individuals
involved should be evaluated and recorded (ICRP, 1992). Effective doses from the
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various radiation procedures that are to be performed can be summed to give an
indication of the possible overall radiation-related health detriments that may accrue
to the volunteers. Effective dose is particularly useful because the procedures per-
formed may involve different dose distributions within the body, but it should be
recognised that it is estimated for a reference person, so when considering the poten-
tial radiation-related risks, the age, sex, and health status of the volunteers should be
taken into account.
4.5. Reporting of unintended exposures
Effective dose can provide enough information for assessments of unintended
exposures and overexposures of patients in diagnostic procedures due to procedural
errors or equipment faults. It can be assessed during incident investigations and
included in reports (Martin et al., 2017). For more substantial exposures that may
approach or exceed 100 mSv, estimates of risk using the best scientific data will be
appropriate.
4.6. Efficacy of imaging for health screening or non-medical
applications
Effective dose can be used in the evaluation of health screening procedures that
involve exposure of many organs within the trunk.
4.7. Doses to carers
Medical exposures are considered to include exposures incurred knowingly and
willingly by individuals helping in the support and comfort of patients undergoing
diagnosis or treatment. This application is more akin to that in occupational expos-
ure, and methods for the prediction of values for effective dose are similar. A typical
example where this might be required is the exposure of family members from a
patient discharged after thyroid treatment with unsealed 131I. The effective doses that
might be received by the individuals involved and the acceptability will be deter-
mined by the individual circumstances (ICRP, 2007).
4.8. Education and training of clinicians and other healthcare
professionals
It is often difficult for clinicians who refer patients and perform medical proced-
ures involving radiation to take potential risks into account when requesting or
justifying patient diagnostic or interventional exposures (ICRP, 2009; Loose et al.,
2009; Zanzonica and Stabin, 2014). Effective dose provides a single value which can
be used to compare different exposure scenarios, and a knowledge of typical effective
doses from common procedures should be included in the education and training of
medical practitioners. Effective dose is an appropriate quantity for straightforward
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communication when explaining possible risks to patients, and allows comparisons
of the possible health risks of an exposure with risks from other exposure scenarios.
4.9. Use of collective effective dose for medical exposures
Effective dose has been used in evaluating the level of exposure in different coun-
tries (UNSCEAR, 2008). The use of collective effective dose in this way has been
used for deriving average population dose per caput from medical exposures. It has
contributed to the raising of awareness of doses from medical procedures in the USA
(NCRP, 2009, 2019) and UK (Wall et al., 2011), and optimisation efforts following
on from these surveys have led to significant reductions in doses from medical pro-
cedures. However, extending the use of collective effective dose to predict health
effects should be treated with caution.
5. CONCLUSIONS
Effective dose in medicine provides a tool that can aid judgements that have to be
made about diagnostic examinations and patient management relating to the level of
risk. Values of effective dose can be derived from measurable quantities and com-
parisons made between medical procedures using different imaging modalities or
exposing different regions of the body. Effective dose has proved to be a valuable
tool in medicine, providing a single dose quantity for communication with clinicians
and patients. Doctors who refer patients or perform medical procedures involving
radiation may have little understanding of the potential health detriment from radi-
ation exposure, and a knowledge of typical effective dose values for common medical
procedures is used in training medical professionals and informing judgements on
relative radiation dose levels. Such information is then used in making everyday
decisions; for example, as part of the referral and justification process for imaging
exposures for individual patients, and in the selection of appropriate imaging
techniques.
A forthcoming ICRP publication discusses the use of protection quantities, and
concludes that effective dose can be used as an approximate indicator of possible
risk. There are substantial uncertainties in the estimation of risk at low doses, recog-
nising that the doses under consideration are likely to be below the levels at which
direct epidemiological observations of excess cases of cancer are available. However,
the most straightforward interpretation of the available scientific evidence for the
purposes of radiological protection is that a nominal lifetime fatal cancer risk esti-
mate of approximately 10-4–10-5 per Sv applies at low doses or low dose rates. The
evidence also shows differences in risk between males and females, and particularly
with age at irradiation. Such differences can be taken into account when considering
risks to individuals. It is emphasised that situations that require best estimates of risk
should be evaluated using the best scientific data – including organ/tissue absorbed
doses; relative biological effectiveness estimates; and age-, sex- and population-
specific risk estimates – with consideration of uncertainties.
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The use of effective dose has helped to raise awareness of dose levels from diag-
nostic imaging procedures among healthcare staff. However, users often forget the
approximations made in the derivation of effective dose, and overstate its accuracy.
Effective dose is only accurate to perhaps 40% as a relative indicator for a refer-
ence person; as such, it should not be stated to more than two significant figures. Use
of effective dose to predict the risk of cancer induction from a low-dose radiation
imaging procedure introduces much greater uncertainties, so descriptive terms are
recommended for conveying risk which reflect uncertainties in risk predictions. These
terms are sufficient in many cases because the risks from most medical diagnostic
exposures are small. If it is considered necessary to calculate a more accurate assess-
ment of risk, this should be based on doses to all of the exposed organs and risk
coefficients used for a person of the same age and sex, with appropriate consideration
of uncertainties.
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